Member Info for Peelweight

Thanks Matterhorn. I am not worried about anything in this article. It is titled to suggest there is a problem with finding treatments for early COVID19. It then goes on to exclude many lines of possible treatment. The only one it doesn’t fully exclude is SNG001. The thrust of its headline, which it hammers home in the text is that it doesn’t help the 90% of people that are ok with paracetamol. I don’t find that much of a criticism but it fits with the headline.

Matterhorn, it can only be done at the prearranged “peeks” into the trial by the Data Monitoring Committee. I have never had seen the full trial protocol to know the plan. The protocol is a big document, maybe 30-100 pages for a modern RCT, and will include the plan for the DMC. All only my best guess obviously

Hi everyone, thanks for this thread and to Bosi for finding this info. To be clear this is no third party site. This is THE ethics committee that gave ethical approval for the multinational trial (Riverside). And we are looking at a recent update 20/7/21.

The dates do make sense if you only look at the primary and secondary outcomes within the text in this ethics approval. The longest secondary outcome is 35 days. It's 35 days between 1/10/21 and 5/11/21.

It is true that 90day data is being sought and the US site lists that. However, I believe this is the latest and most likely to be accurate estimate of last patient recruited -1/10/21. I'm a little heartbroken to see we will struggle to EUA prior to winter in N Hemisphere.

There are two caveats that may help
1) the data monitoring committee may call a premature end to recruitment if it is unethical to continue as proven effective. This would stop recruitment early.

2) a country could EUA anytime they feel they have enough provisional data to take that step and would continue to monitor the data collection. This seems less likely to me

Yes, that's what RM has said many times to the market

It is us. There's a link to the SNG001 Patient Information sheet. I am disappointed to note it is still on the website as "you will be enrolled in part 1" of the study. There is mention of a part two in the previous page. It may be out of date (it says SNG001 is a combination of two drugs so there must be some copy and paste errors from the Antibody crocktails).

My understanding here is that part 1 refers to P2, and part 2 refers to P3, in ACTIV 2

I could be wrong, wouldn't be the first time!

Also, I had little hope for the HT and was delighted to see a cohort that could and should be studied. I saw the HT results as positive and helpful and was staggered to see the dumping of stock. Took the chance to add a lump at 98p, wish I had had more funds available that day!

WPA, I believe that our home trial has indeed narrowed the possible out-patient subset to “marked or severe breathlessness”. And I believe that any promotion into P3 of ACTIV 2, which may have happened as part of the original plan pending full P2 readout being in public domain, would only include that subset of patients.

That is the enormous strength of the HT readout IMO.

Interesting thought Matterhorn. Though wouldn’t explain why Synairgen Ltd has started describing itself as a Pharma Company recently?

Tornado, compelling narrative. You aren't just a wizard with the charts but a talented storyteller!

https://www.clinicaltrials.gov/ct2/show/NCT04732949?term=synairgen&cond=Covid19&draw=2&rank=2

With 64 sites recruiting for SPRINTER on the NIH pages since 30 th June, and top sleuthing by others (Matterhorn and others) on this board suggesting more, it is highly likely the H2 reporting schedule will be hit IMO

I remain confident of an EUA application in the next 5 months and 12 days. Patience required I fear

0.12%, not 1.2%

Happy Birthday Enrico!

Hi Teamwork, agreed re speed. Please also note it doesn't move to ACTIV3. If we are progressed, we move to P3 of ACTIV2 (which is the ACTIV that looks for outpatient treatments)

Welsh, big Pharmas would and do buy into their development pipeline years prior to full approvals. I agree with Jint, Synairgen and it’s IIs just simply wouldn’t sell out at this stage as if P3 replicates P2, then multibag territory. The board would not recommend any offer at this stage. IMHO

Sorry, Babycham. My spelling is indeed distasteful!

And a cheeky wee Babysham for each "bag" of the multi-bagger wouldn't break this rule hopefully??

Noted, thanks Jez

I'd love to hear from Tornadotony about the week graph.

Big step up to 125+, then a big step up to 140, then todays big step up to 158+

It looks like there has been a large buyer that has been hoovering up stock/filling an order at three different price points??